{"id":44115,"date":"2022-05-19T14:01:33","date_gmt":"2022-05-19T12:01:33","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\/"},"modified":"2022-05-19T14:01:33","modified_gmt":"2022-05-19T12:01:33","slug":"pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\/","title":{"rendered":"Pear Therapeutics to Host Inaugural Virtual Investor Day on June 6, 2022"},"content":{"rendered":"<div>\n<p>BOSTON&#8211;(BUSINESS WIRE)&#8211;Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it will host an inaugural virtual Investor Day on June 6, 2022, at 10:00 a.m. \u2013 12:30 p.m. ET.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220519005236\/en\/754943\/5\/Logo-Pear-Therapeutics-Final.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220519005236\/en\/754943\/21\/Logo-Pear-Therapeutics-Final.jpg\"><\/a><\/p>\n<p>\nPear\u2019s Investor Day will feature presentations by members of the management team. The company will provide updates on the continuum of evidence and commercial progress for its three commercial products for substance use disorder, opioid use disorder, and chronic insomnia, and detail the expansion of access to PDTs.\n<\/p>\n<p>\nA live webcast will be available under <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.peartherapeutics.com%2Fnews-events%2Fevents-presentations&amp;esheet=52723970&amp;newsitemid=20220519005236&amp;lan=en-US&amp;anchor=%26%238220%3BNews+and+Events%26%238221%3B&amp;index=1&amp;md5=150a9772e66157284fafaf8f1e348bd9\" rel=\"nofollow noopener\" shape=\"rect\">\u201cNews and Events\u201d<\/a> in the Investors section of the Pear website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.peartherapeutics.com&amp;esheet=52723970&amp;newsitemid=20220519005236&amp;lan=en-US&amp;anchor=investors.peartherapeutics.com&amp;index=2&amp;md5=5aa119b0fb820e28ab30d96cfd19e0bd\" rel=\"nofollow noopener\" shape=\"rect\">investors.peartherapeutics.com<\/a>. A replay of the webcast will be available on Pear\u2019s website for up to 30 days following the event.\n<\/p>\n<p>\n<b>About Pear Therapeutics<\/b>\n<\/p>\n<p>\nPear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear\u2019s product, reSET<sup>\u00ae<\/sup>, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear\u2019s second product, reSET-O<sup>\u00ae<\/sup>, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear\u2019s third product, Somryst<sup>\u00ae<\/sup> for the treatment of chronic insomnia, was the first PDT submitted through FDA\u2019s traditional 510(k) pathway while simultaneously reviewed through FDA\u2019s Software Precertification Pilot Program. For more information, visit Pear at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.peartherapeutics.com%2F&amp;esheet=52723970&amp;newsitemid=20220519005236&amp;lan=en-US&amp;anchor=www.peartherapeutics.com&amp;index=3&amp;md5=3451b1e1781a50135555a8f84fb9e142\" rel=\"nofollow noopener\" shape=\"rect\">www.peartherapeutics.com<\/a>.\n<\/p>\n<p>\n<b>Forward-Looking Statements from Pear Therapeutics<\/b>\n<\/p>\n<p>\nCertain statements and projections in this press release may be considered forward-looking statements within the meaning of the federal securities laws. Forward looking statements generally relate to future events or involving, or future performance of, Pear. For example, statements regarding the expansion of access to PDTs are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as \u201cmay\u201d, \u201cwill\u201d, \u201caim\u201d, \u201cestimate\u201d, \u201canticipate\u201d, \u201cbelieve\u201d, or \u201ccontinue\u201d, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements.\n<\/p>\n<p>\nThese forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Pear and its management are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) delay or reluctance by patients and\/or providers to adopt, request or use Pear\u2019s products, (ii) changes in applicable laws or regulations; and (iii) other risks and uncertainties set forth in Pear\u2019s future filings with the SEC. These filings will identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.\n<\/p>\n<p>\nReaders are cautioned not to put undue reliance on forward-looking statements, and Pear assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Pear gives no assurance that Pear will achieve its expectations. The inclusion of any statement in this communication does not constitute an admission by Pear or any other person that the events or circumstances described in such statement are material.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media and Investors:<\/b><br \/>Meara Murphy<br \/>\n<br \/>Senior Director, Corporate Communications<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;&#105;l&#x74;&#x6f;&#58;m&#x65;&#x61;&#114;a&#x2e;&#x6d;&#117;r&#x70;&#x68;&#121;&#64;&#x70;&#x65;&#97;r&#x74;&#x68;&#101;&#114;a&#x70;&#x65;&#117;t&#x69;&#x63;&#115;&#46;&#x63;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#109;&#101;&#x61;r&#97;&#x2e;&#x6d;u&#114;&#x70;&#x68;y&#64;&#x70;e&#97;&#x72;&#x74;h&#101;&#x72;&#x61;p&#101;&#x75;t&#105;&#x63;&#x73;&#46;&#99;&#x6f;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON&#8211;(BUSINESS WIRE)&#8211;Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it will host an inaugural virtual Investor Day on June 6, 2022, at 10:00 a.m. \u2013 12:30 p.m. ET. Pear\u2019s Investor Day will feature presentations by members of the management team. The company &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44115","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pear Therapeutics to Host Inaugural Virtual Investor Day on June 6, 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pear Therapeutics to Host Inaugural Virtual Investor Day on June 6, 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BOSTON&#8211;(BUSINESS WIRE)&#8211;Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it will host an inaugural virtual Investor Day on June 6, 2022, at 10:00 a.m. \u2013 12:30 p.m. ET. Pear\u2019s Investor Day will feature presentations by members of the management team. The company ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-19T12:01:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220519005236\/en\/754943\/21\/Logo-Pear-Therapeutics-Final.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Pear Therapeutics to Host Inaugural Virtual Investor Day on June 6, 2022\",\"datePublished\":\"2022-05-19T12:01:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\\\/\"},\"wordCount\":647,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220519005236\\\/en\\\/754943\\\/21\\\/Logo-Pear-Therapeutics-Final.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\\\/\",\"name\":\"Pear Therapeutics to Host Inaugural Virtual Investor Day on June 6, 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220519005236\\\/en\\\/754943\\\/21\\\/Logo-Pear-Therapeutics-Final.jpg\",\"datePublished\":\"2022-05-19T12:01:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220519005236\\\/en\\\/754943\\\/21\\\/Logo-Pear-Therapeutics-Final.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220519005236\\\/en\\\/754943\\\/21\\\/Logo-Pear-Therapeutics-Final.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pear Therapeutics to Host Inaugural Virtual Investor Day on June 6, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pear Therapeutics to Host Inaugural Virtual Investor Day on June 6, 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\/","og_locale":"en_US","og_type":"article","og_title":"Pear Therapeutics to Host Inaugural Virtual Investor Day on June 6, 2022 - Pharma Trend","og_description":"BOSTON&#8211;(BUSINESS WIRE)&#8211;Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it will host an inaugural virtual Investor Day on June 6, 2022, at 10:00 a.m. \u2013 12:30 p.m. ET. Pear\u2019s Investor Day will feature presentations by members of the management team. The company ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-19T12:01:33+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220519005236\/en\/754943\/21\/Logo-Pear-Therapeutics-Final.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Pear Therapeutics to Host Inaugural Virtual Investor Day on June 6, 2022","datePublished":"2022-05-19T12:01:33+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\/"},"wordCount":647,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220519005236\/en\/754943\/21\/Logo-Pear-Therapeutics-Final.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\/","url":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\/","name":"Pear Therapeutics to Host Inaugural Virtual Investor Day on June 6, 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220519005236\/en\/754943\/21\/Logo-Pear-Therapeutics-Final.jpg","datePublished":"2022-05-19T12:01:33+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220519005236\/en\/754943\/21\/Logo-Pear-Therapeutics-Final.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220519005236\/en\/754943\/21\/Logo-Pear-Therapeutics-Final.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-host-inaugural-virtual-investor-day-on-june-6-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Pear Therapeutics to Host Inaugural Virtual Investor Day on June 6, 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44115"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44115\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}